Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Jetrea

- PMLiVE

FDA gives breakthrough status to Xolair for food allergies

Food allergies could open up big new market for biologic

- PMLiVE

Promising more appraisal capacity, NICE revives industry fee idea

Rising workload and shrinking budget making charges inevitable

- PMLiVE

Daily Brief: Sarepta deepens gene therapy investment, NICE changes mind on Besponsa, Digital Medicine company Akili raises $13m

News from pharma, biotech and healthcare

- PMLiVE

First migraine prevention drug to hit European market

European Commission green lights Novartis’ Aimovig

- PMLiVE

Daily Brief: GSK unveils R&D plan, Keytruda OK’d for lymphoma by NICE

News from pharma, biotech and healthcare

Novartis day

Daily brief: Novartis spends big on ezcema, Kite invests, another gene therapy IPO

A round up from pharma, biotech and healthcare

- PMLiVE

Novartis follows Pfizer and freezes US prices this year

And still expects revenues to come in at the high end of expectations for 2018

Novartis launch NET cancer community app

Galaxies of Hope aims to provide support to cancer patients

- PMLiVE

Novartis rejects claims it misled Senate over Cohen links

Report says Novartis discussed drug-pricing with the President’s former ‘fixer’

- PMLiVE

Daily Brief: Health and social care still divided, Opdivo rejected in bladder cancer, Xalkori extends reach

A round-up from pharma, biotech and healthcare

- PMLiVE

Alcon spin-off prompts Novartis downgrade by Moody’s

Selling off Alcon concentrates business in riskier areas

- PMLiVE

CAR-Ts Kymriah and Yescarta step closer to approval in Europe

Final European approval around the corner - but reimbursement and specialist centres among outstanding issues

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links